Tandem Diabetes Care
Behavioral Sciences
Dr. Singh leads the Behavioral Research team at Tandem Diabetes Care and works closely with other members of Behavioral Sciences and cross functional stakeholders to implement real-world observational studies to better understand the use and impact of different therapies on the lives of people with diabetes. As a health psychologist, she is especially passionate about using patient-reported outcome measures to examine experiences with diabetes treatments and developing interventions to improve quality of life with diabetes.

Presenter of 3 Presentations

Applying PROs to define the future of diabetes technology

Session Type
Parallel Session
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 113
Lecture Time
17:05 - 17:20

Real World Patient Experience with Control-IQ technology

Session Type
Industry Symposium
Date
Wed, 27.04.2022
Session Time
14:30 - 16:00
Room
Hall 115
Lecture Time
15:23 - 15:33

LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IRRESPECTIVE OF BASELINE GLYCEMIC CONTROL AND PREVIOUS INSULIN DELIVERY METHOD WITH THE T:SLIM X2 PUMP WITH CONTROL-IQ TECHNOLOGY

Session Type
Oral Presentations Session
Date
Sat, 30.04.2022
Session Time
11:00 - 12:30
Room
Hall 120
Lecture Time
11:48 - 11:56

Abstract

Background and Aims

Patient-reported outcomes (PROs) are essential when evaluating patients’ trust in their diabetes therapy and its long-term use. Previous publications from the Control-IQ Observational (CLIO) study (NCT04503174) have shown PRO improvements in people with type 1 diabetes (PWT1D) after three months of using Control-IQ technology.

Methods

We compared PROs at baseline (pre) and 6 months post Control-IQ technology use in CLIO participants. Repeated measures ANOVA was used to assess differences in PROs from pre to post.

Results

Sample included 2062 PWT1D. At baseline, 23% reported HbA1c ≥8.5%, and 63% were using a different insulin pump. After 6 months of Control-IQ technology (post), participants reported significant reduction in the perceived negative impact of diabetes on their diabetes-specific quality of life (mean=4.70 (SD=0.88) vs. 4.40 (1.05), p<0.001) with greatest improvement reported for “freedom to eat as you wish”. Significant improvement in satisfaction with insulin-delivery device (IDD) was noted at post, with participants reporting higher satisfaction with Control-IQ technology (8.84 (1.14) vs. their previous IDD (7.21 (1.97)) (p<0.001). Improved satisfaction was reported across all age groups (e.g., 6–12-year-old: 8.99 (1.01); 65+ years: 8.66 (1.33)). Additionally, reduced burden of diabetes was reported irrespective of previous IDD (MDI: 4.80 (1.85) vs. 3.15 (1.49); Pump users: 4.59 (1.81) vs. 3.10 (1.39); p<0.001) and baseline HbA1c (<8.5%: 4.90 (1.84) vs. 3.05 (1.35); ≥8.5%: 4.88 (1.86) vs. 3.29 (1.50); p<0.001).

Conclusions

Control-IQ technology users reported improved quality of life, reduced diabetes burden, and higher satisfaction with diabetes therapy irrespective of age, baseline HbA1c, and previous IDD.

Hide